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Introduction {#sec1}
============

Biological acids play key roles in the innate immune responses of eukaryotic hosts. To counteract acid-mediated defense mechanisms, encountered at extracellular or intracellular levels, pathogens have evolved a range of strategies. In the extracellular context, *Escherichia coli*, *Vibrio cholerae*, or *Salmonella typhimurum* have elaborated sophisticated strategies to survive in the harsh acidic conditions of gastrointestinal tracts ([@bib9]). In the intracellular context, since Metchnikoff (who reported in 1905 that acidic reactions can be observed in the phagosomes of guinea pig macrophages upon ingestion of bacteria), numerous studies have elucidated mechanisms used by pathogens to overcome acid-mediated defense strategies of macrophages ([@bib12]). Pathogens use different strategies to avoid or to resist to progressive phagosomal maturation, either interfering with phagosomal trafficking or adapting to the harsh environment of the phagosome ([@bib8]). For example, *Listeria monocytogenes* secretes pore-forming listeriolysin, which induces a rapid collapse of the phagosomal membrane, thereby promoting bacterial escape into the cytosol ([@bib10]). *Coxiella burnetii* modifies its gene expression to undergo active replication in large acidic vacuoles ([@bib20]). For *Mycobacterium tuberculosis* (*Mtb*), intracellular survival requires the regulation of pH homeostasis inside the vacuole, stabilizing the phagosomal acidification around pH 6.3--6.5. It was previously suggested that, in this case, such stabilization is caused by a defective retention of the V-ATPase complex at the phagosome ([@bib21], [@bib31]). Accounting for this phenomenon, it was shown that the microbial tyrosine phosphatase PtpA (Rv2234) prevents the tethering of V-ATPase to the *Mtb*-containing vacuole ([@bib37]). More broadly, many mycobacterial products have been shown to arrest phagosome maturation and acidification, such as lipoarabinomannan, trehalose dimycolate, or acyltrehalose-containing glycolipids ([@bib5], [@bib21], [@bib22]). Whereas it is considered that the *Mtb* phagosome remains immature ([@bib1], [@bib27]), studies showed that *Mtb* is able to induce phagosomal rupture at later stages of infection ([@bib28], [@bib33]). This capacity depends on a functional ESX-1 type VII secretion system and requires control of phagosomal acidification ([@bib29]). These findings shed new light on the multifaceted question of how *Mtb* counteracts phagosomal acidification. Altogether, these observations hint to the possible existence of alternative mechanisms, which could be used by pathogenic mycobacteria to block phagosomal acidification.

To address this important question, we investigate here the various macrophage pathways susceptible to being manipulated by *Mtb* during infection, resorting to genome-wide RNAi high-content screening in *Mtb*-infected macrophages. By this approach, we identified cytokine-inducible SH2-containing protein (CISH) as a pivotal host factor contributing to the growth of *Mtb* in macrophages. CISH was originally identified as the first member of the suppressor of cytokine signaling (SOCS) family of proteins, which comprises eight members (CISH and SOCS1 to SOCS7) that are all key immunity regulators known to control cytokine signaling by inhibiting JAK/STAT activity ([@bib38], [@bib39], [@bib40]). We further show that entry of *Mtb* in macrophages induces rapid release of granulocyte-macrophage colony-stimulating factors (GM-CSFs), triggering STAT5 signaling and leading to early CISH expression. Moreover, we demonstrate an enrichment of CISH around *Mtb*-containing phagosomes, with the protein targeting the catalytic subunit A of V-ATPase (ATP6V1A) for ubiquitination, thus promoting its degradation.

Results {#sec2}
=======

CISH Promotes *Mtb* Replication {#sec2.1}
-------------------------------

To study the effect of Cish on intracellular replication of *Mtb*, we used the visual phenotypic assay in murine macrophages (RAW 264.7) that relies on the automated monitoring, by confocal fluorescent microscopy, of intracellular growth of GFP-expressing *Mtb* H37Rv (H37Rv-GFP) ([@bib7], [@bib24]). Macrophages were first transfected with two small interfering RNAs (siRNAs) targeting Cish following established protocols ([@bib6]) and then infected with H37Rv-GFP. Cells were further incubated for 5 days before counterstaining with whole-cell dye SYTO60 and were analyzed with image acquisition using an Opera automated confocal microscope. Non-targeting siRNAs (scramble siRNAs) alone and in combination with isoniazid (INH) were used as negative and positive controls, respectively ([Figure 1](#fig1){ref-type="fig"}A). Customized image analysis was used for the quantification of relevant parameters, such as the number of macrophages, the percentage of infected cells, and the bacterial area per infected cell ([@bib7], [@bib24]). A decrease in the percentage of infected cells for Cish-silenced samples relative to non-targeting controls was observed, suggesting that Cish either inhibits *Mtb* intracellular replication or contributes to increased death of *Mtb* ([Figures 1](#fig1){ref-type="fig"}A and 1B). The role of Cish in promoting bacterial replication was confirmed by the relative numbers of colony-forming units (CFUs) per cell, with a decrease in the numbers of viable bacteria per cell for Cish-silenced samples relative to scramble controls ([Figure 1](#fig1){ref-type="fig"}C). Corroborating these results, the bacterial load at 5 days post-infection (p.i.) was about 2-fold lower in bone marrow-derived macrophages (BMDMs) from Cish knockout (KO) mice than in BMDMs from wild-type (WT) mice ([Figure 1](#fig1){ref-type="fig"}D).Figure 1Cish Promotes *Mtb* Replication(A) Typical confocal microscope images obtained in macrophages transfected with non-targeting siRNA controls (scramble) or Cish siRNA duplexes (siCishA or siCishB) or treated with 5 μg/mL of INH at 5 days p.i. with H37Rv-GFP. SYTO60-labeled cells are in red, and H37Rv-GFP bacteria are in green. Scale bar, 5 μm.(B) Quantification of *Mtb* H37Rv intracellular growth in macrophages silenced for Cish with siRNA duplexes A (black solid circles on solid lines) and B (black solid triangles on solid lines). Positive controls (scramble siRNA + INH, gray solid squares on dotted lines) and negative controls (scramble siRNA, gray open squares on dashed lines), as assessed by monitoring the percentage of infected RAW 264.7 cells. For each time point, the percentage was normalized to that observed at 5 hr p.i. (T0 p.i.). Reported values represent fold changes (Tx/T0) ± SD.(C) CFU numbers at 5 days p.i. normalized to the number of macrophages (T5). Results are means ± SD from representative experiments performed in duplicate. Positive control: INH, 5 μg/mL.(D) Image-based quantification of the intracellular replication of H37Rv-GFP at 5 days p.i. in BMDM from Cish KO and WT mice.(E) CFU determination in the lungs of Cish KO and WT mice challenged with *Mtb* H37Rv at 0, 21, and 42 days. Quantification represents the average of log of CFUs in lung ± SD. n = 4 mice per group per time point. Experiment was performed twice.^∗^p \< 0.05, ^∗∗^p \< 0.01.

We found that in an in vivo murine infection model, the number of *Mtb* CFUs in the lungs of Cish KO mice was lower than that in WT control animals ([Figure 1](#fig1){ref-type="fig"}E). Although soon after intranasal challenge with *Mtb* H37Rv, the colonization of the lungs was found to be similar for infected Cish WT mice, the numbers of CFUs in lungs were 10-fold lower for Cish KO mice relative to WT mice during the acute replication phase. These results point to a counter-intuitive role for this host protein in promoting *Mtb* replication in the early stage of infection. We next decided to assess whether CISH is also required for *Mtb* survival in human macrophages. We first ascertained that our reverse transfection of pooled siRNAs targeting CISH did not induce cytotoxicity and validated the silencing efficiency by qRT-PCR ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). The intracellular bacterial load upon *Mtb* infection was then quantified as earlier ([@bib7], [@bib24], [@bib25]). The bacterial load at 3 hr p.i. was the same for small interfering CISH (siCISH) human macrophages and for scramble control, whereas at 4 days p.i., the bacterial load in siCISH human macrophages was two times lower than that in controls ([Figure S1](#mmc1){ref-type="supplementary-material"}C). These results strongly suggest that CISH plays a role in enhancing the intracellular replication of *Mtb*, both in murine and human macrophages and in an in vivo mouse infection model.

CISH Is Recruited at the *Mtb* Vacuole and Interferes with Phagosome Acidification {#sec2.2}
----------------------------------------------------------------------------------

To understand how CISH promotes *Mtb* replication, we first quantified the expression of Cish. Cish was absent in naive macrophages, while its transcription was rapidly upregulated upon infection, with a peak of expression at 3 hr p.i. ([Figure 2](#fig2){ref-type="fig"}A). This result is consistent with a previous report of increased Cish expression in murine primary macrophages infected with *Mtb* ([@bib14]). Accordingly, expression of Cish was detected 3 hr p.i. by western blot and maintained up to 24 hr ([Figure 2](#fig2){ref-type="fig"}B). Immunofluorescence studies revealed that Cish was recruited at the *Mtb*-containing vacuole with about 30% of phagosomal bacteria positive for Cish 6 hr p.i. and 55% after 24 hr ([Figure 2](#fig2){ref-type="fig"}C). A similar accumulation of CISH on phagosomes was seen in human macrophages. CISH was also recruited at the phagosome by dead *Mtb*; however, only live *Mtb*-infected human macrophages retained CISH at the vacuole at 24 hr p.i. ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). The question then arises whether CISH can play a role in the inhibition of phagosome maturation. We thus monitored the fusion of *Mtb* phagosomes with lysosomes by fluorescence microscopy, using the pH-sensitive LysoTracker dye. It was demonstrated previously that the intensity of LysoTracker-labeling directly correlates with the presence of acidic lysosomal milieu in *Mtb* vacuoles ([@bib5]). Upon *Mtb* infection, the LysoTracker intensity was significantly higher in macrophages silenced for Cish than that in scramble ([Figure 2](#fig2){ref-type="fig"}D), strongly suggesting that Cish interferes with the process of phagolysosomal fusion. The existence of a link between accumulation of CISH and restriction of phagosomal acidification was confirmed in siCISH *Mtb*-infected human macrophages upon monitoring mean pHrodo intensity levels per *Mtb*-containing phagosomes ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Compared to scramble human macrophages, bacterial phagosomes from siCISH human macrophages exhibited a significant increase in pHrodo fluorescence intensity, indicative of stronger phagosomal acidification in CISH-silenced cells ([Figures S2](#mmc1){ref-type="supplementary-material"}D--S2G). Most mycobacterial phagosomes in scramble human macrophages displayed a characteristic pH between 6 and 7, whereas in siCISH human macrophages, most of the phagosomes appeared more acidic, with a pH between 5 and 6 ([Figure S2](#mmc1){ref-type="supplementary-material"}H).Figure 2Cish Is Recruited at the *Mtb* Vacuole and Interferes with Phagosome Acidification(A) Cish mRNA levels in RAW 264.7 macrophages infected with *Mtb* H37Rv (black bars) compared with non-infected (NI) ones (gray bars). Results are means ± SD from representative experiments performed in triplicate.(B) Cish expression analysis by immunoblotting. α/β-tubulin served as internal controls.(C) Analysis of the intracellular localization of Cish by fluorescence microscopy. Nuclei were labeled with DAPI (blue), and Cish was immunolabeled using Cish antibody (red). *Mtb* H37Rv-GFP is in green. Plot represents the percentage of *Mtb* H37Rv-GFP bacteria that colocalize with Cish.(D) Typical images and related quantification of phagosome acidification of NI, *Mtb* H37Rv-GFP-infected macrophages transfected with scramble control siRNA (scramble), or Cish siRNA duplexes (siCishA). DAPI-labeled cell nuclei are in blue, *Mtb* H37Rv-GFP is in green, and acidic-pH-sensitive LysoTracker staining is in red. The LysoTracker signal was set to minimum in NI controls.Scale bars, 10 μm. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.

We then wanted to pinpoint the mechanism underlying such an effect of CISH. Because CISH has the ability to ubiquitinate proteins, targeting them for the ubiquitin-dependent proteasomal degradation ([@bib23], [@bib39]), we investigated the effect of CISH on protein ubiquitination and proteasome activity. We assessed such an impact at 24 hr p.i. when CISH accumulated mostly around *Mtb*-containing phagosomes. siCISH *Mtb*-infected human macrophages were then labeled for poly-ubiquitin motifs, and the mean levels of poly-ubiquitin signals per cell were assessed using dedicated image-analysis software. Such analyses revealed that siCISH human macrophages exhibited a strong decrease in poly-ubiquitin fluorescence intensity compared to scramble ones ([Figures 3](#fig3){ref-type="fig"}A and 3B), showing that CISH induced ubiquitination of proteins. Because protein poly-ubiquitination leads to proteasomal degradation, we questioned whether the decrease of poly-ubiquitin signals in siCISH macrophages was associated with a decreased eukaryotic proteasome activity. The proteasome activity in *Mtb*-infected human macrophages was thus monitored by quantification of the cleavage of fluorogenic LLVY-R110 proteasome substrates ([Figure S3](#mmc1){ref-type="supplementary-material"}). We found that the proteasome activity was significantly decreased in siCISH conditions, relative to scramble ([Figure 3](#fig3){ref-type="fig"}C). Given the involvement of CISH in ubiquitination and proteasome activities in *Mtb*-infected macrophages, we therefore wanted to identify the proteins susceptible to be targeted by CISH for proteasomal degradation.Figure 3CISH Targets the Subunit A of V-ATPase for Ubiquitination(A) Typical confocal microscope images of *Mtb*-infected human macrophages that were labeled with antibody targeting poly-ubiquitin (poly-Ub) motifs. DAPI-labeled cell nuclei are in blue, *Mtb* H37Rv-DsRed is in red, and poly-ubiquitin conjugated proteins are in green. White squares delimitate the area magnified in the upper-right corners of the various micrographs. Scale bar, 50 μm.(B) Mean poly-ubiquitin signal intensity per cell. Plotted values are for siCISH sample cells (N = 1,900 cells) and scramble controls (N = 2,400 cells).(C) Monitoring proteasome activity in siCISH and scramble samples upon infection with *Mtb* H37Rv by quantification of fluorescence, resulting from the cleavage of LLVY-R110. As negative controls, scramble human macrophages were treated for 4 hr with 1 μM MG132 proteasome inhibitor (MG132 +).(D) Ubiquitination profile of ATP6V1A in siCISH and scramble human macrophages 24 p.i. by *Mtb* H37Rv monitored by western blot. 5 hr before lysis, cells were incubated in the presence of 1 μM MG132 and ATP6V1A was immunoprecipitated from whole-cell lysate (top panel). As control, the amount of ATP6V1A in whole-cell lysate was ascertained by probing with anti-ATP6V1A and anti-α/β-tubulin (lower panel).(E) Intracellular localization of CISH and ATP6V1A analyzed by confocal microscopy in human macrophages. H37Rv-GFP bacteria are in blue, CISH is in green, and ATP6V1A is in red. The white line represents a section of the picture used to quantify the intensity of fluorescence for both CISH and ATP6V1A. Values of intensities of CISH (green) and ATP6V1A (red) are plotted next to the micrograph.(F) Intracellular colocalization of CISH and ATP6V1A, analyzed by fluorescence confocal microscopy in *Mtb*-infected human macrophages treated with DMSO (H37Rv) or 1 μM MG132 for 5 hr. CISH and ATP6V1A colocalization was assessed by calculating Pearson's correlation between CISH and ATP6V1A fluorescence intensities around phagosomes (N = 150 phagosomes).All micrographs and plots are representative of two independent experiments, each made in duplicate. ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.

CISH Targets ATP6V1A for Ubiquitination {#sec2.3}
---------------------------------------

We implemented a high-throughput proteomic approach to identify proteins ubiquitinated by CISH, comparing the set of ubiquitinated proteins found in *Mtb*-infected siCISH human macrophages with that found in scramble ones. For each sample, ubiquitinated proteins were first purified by pull-down of total protein extracts with the UbiQapture-Q matrix and then analyzed using tandem mass spectrometry ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Based on this analysis, 1,282 ubiquitinated proteins were detected in siCISH samples, compared to 1,556 proteins in scramble samples. A more stringent comparison, with scoring taking into account the number of peptides and spectra in the tandem mass spectrometry, allowed the selection of 65 potential CISH targets, with the corresponding proteins being significantly less abundant in the CISH-silenced conditions relative to scramble controls ([Figures S4](#mmc1){ref-type="supplementary-material"}B and S4C; [Table S1](#mmc2){ref-type="supplementary-material"}). Among the CISH-targeted proteins, we identified ATP6V1A, which is part of the V-ATPase multi-subunit complex that had previously been shown not to be present at the non-acidified *Mtb* phagosome ([@bib31], [@bib32]). We thus tested whether the ubiquitination of ATP6V1A by CISH could interfere with the acidification process. First, we confirmed by immunoprecipitation the ubiquitination of ATP6V1A, as seen 24 hr after *Mtb* infection ([Figure 3](#fig3){ref-type="fig"}D). To avoid proteasomal degradation that could impair the detection of ATP6V1A, macrophages were treated for 5 hr with proteasome inhibitor MG132 before cell lysis. In such conditions, ubiquitin signals were not detected in siCISH samples, in contrast to scramble controls ([Figure 3](#fig3){ref-type="fig"}D).

We next compared the distributions of CISH and ATP6V1A specifically at the level of *Mtb*-containing phagosomes. Confocal image acquisition of infected macrophages revealed a patchy distribution for ATP6V1A throughout cells ([Movie S1](#mmc3){ref-type="supplementary-material"}). At the phagosome, CISH and ATP6V1A display largely superimposable fluorescence intensity profiles ([Figure 3](#fig3){ref-type="fig"}E). A quantitative analysis on a large set of phagosomes led to a significant correlation between the distribution of CISH and that of ATP6V1A ([Figure 3](#fig3){ref-type="fig"}F). This correlation takes into account the distribution of the two proteins around the phagosomes. In addition, the correlation coefficient increased to a value larger than 0.4 upon treatment with proteasome inhibitor MG132, suggesting that ubiquitination of ATP6V1A by CISH leads to its degradation by the proteasome.

CISH activity was previously shown to be mediated by its C-terminal SOCS box domain, which is essential for the interaction of CISH with various proteins, as well as with the Cullin-RING E3 ubiquitin ligase complex, leading to the ubiquitin labeling of target proteins for proteasomal degradation ([@bib11], [@bib18], [@bib23], [@bib41]). For example, CISH has been shown to induce the degradation of growth hormone receptor, erythropoietin receptor, and Bcl-2-interacting mediator of cell death extra long (BimEL) ([@bib15], [@bib34], [@bib42]). In this general structural background, we wanted to ascertain (1) the direct physical interaction of CISH with intracellular ATP6V1A and (2) the proteasomal degradation of ATP6V1A. First, to assess the physical interactions between CISH and ATP6V1A, we resorted to HEK293 cells that we engineered to overexpress murine Cish or CishΔSOCS box ([Figure 4](#fig4){ref-type="fig"}A). To get a comparable amount of proteins in the two samples, cells were first treated with proteasome inhibitor MG132 for 5 hr before lysis. Endogenous ATP6V1A was then immunoprecipitated and Cish was detected by western blot ([Figure 4](#fig4){ref-type="fig"}B; [Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B). Cish was found complexed to ATP6V1A in samples overexpressing Cish, but not in control ones. In contrast, we found that in the absence of the SOCS box domain, the binding of Cish to ATP6V1A was strongly weakened, suggesting that the SOCS box domain is required for an optimal binding ([Figure 4](#fig4){ref-type="fig"}B). Second, to ascertain the link between Cish and ATP6V1A degradation, we compared the respective intracellular amounts of ATP6V1A in HEK-expressing Cish or CishΔSOCS box in the absence of the proteasome inhibitor ([Figure 4](#fig4){ref-type="fig"}C). These comparisons showed that the amount of intracellular ATP6V1A was drastically lower in HEK-expressing Cish than in HEK control (pcDNA), confirming that Cish modulates the degradation of ATP6V1A. Moreover, in the absence of the Cish SOCS box domain, ATP6V1A was detectable in large amounts in cell lysates, demonstrating that the expression of functional Cish is required for the degradation of ATP6V1A ([Figure 4](#fig4){ref-type="fig"}C). Finally, we performed experiments to assess whether the degradation of ATP6V1A was mediated by the proteasome. To this end, HEK-expressing Cish samples were treated with proteasome inhibitor MG132 at different time points. In the presence of MG132, both Cish and ATP6V1A accumulated within cells, suggesting that the intracellular turnover of these two proteins was mediated by the proteasome ([Figure 4](#fig4){ref-type="fig"}D). From these results, a mechanistic model can be drawn for the inhibition of phagosomal acidification, in which CISH interferes with V-ATPase through the ubiquitination and subsequent proteasomal degradation of its subunit A.Figure 4Ubiquitination of ATP6V1A by Cish Leads to Its Subsequent Proteasomal Degradation(A) Schematic representations of Cish full sequence (Cish) and Cish deleted from its SOCS box domain (ΔSOCS box).(B) Pull-down of Cish following immunoprecipitation of ATP6V1A from HEK293 cells that overexpress Cish or CishΔSOCS box. An empty vector is used as the negative control (pcDNA). In the lower panel, Cish and CishΔSOCS expression from whole-cell lysates were ascertained by probing with anti-Cish and anti-α/β-tubulin (lower panel).(C) Immunodetection of ATP6V1A from pcDNA, Cish, and CishΔSOCS box-overexpressing HEK cells. ATP6V1A was detected by probing with anti-ATP6V1A, and Cish and CishΔSOCS box were detected by probing with anti-Cish. Probing with anti-α/β-tubulin antibodies was used to confirm gel loading. Reported values represent the means of relative expression of ATP6V1A ± SEM from three independent experiments. ^∗^p \< 0.05.(D) Time-dependent accumulation of Cish and ATP6V1A in the presence of 5 μM MG132 proteasome inhibitor. For the quantification (right panel), both ATP6V1A expression and Cish expression were normalized to T0. Reported values represent fold changes (Tx/T0) ± SEM.

Expression of CISH in *Mtb*-Infected Macrophages Depends on STAT5 Activation {#sec2.4}
----------------------------------------------------------------------------

We then investigated the regulation of CISH expression to further elucidate the CISH-associated signaling cascade targeted by *Mtb*. It was reported that the regulation of cell functions involving SOCS proteins is closely connected with the activities of proteins of the STAT family ([@bib38], [@bib39]). In particular, STAT5 and CISH belong to the same negative regulatory loop, because STAT5 can bind the *CISH* promoter region, thereby inducing CISH expression ([@bib26]). Accordingly, we first characterized the early activation of STAT5 during infection of human macrophages with *Mtb*. The amount of phosphorylated STAT5 proteins (PY-STAT5) was quantified by western blot up to 48 hr p.i., and the results showed a strong phosphorylation of STAT5 at 3 hr p.i. ([Figure 5](#fig5){ref-type="fig"}A; [Figure S6](#mmc1){ref-type="supplementary-material"}A). Corroborating this result, the nuclear translocation of PY-STAT5 proteins in *Mtb*-infected human macrophages was monitored by indirect immunofluorescence and image-based quantification, showing that about 26% of human macrophages displayed nuclear translocation of PY-STAT5 proteins 3 hr p.i. ([Figure 5](#fig5){ref-type="fig"}B). We also found that PY-STAT5 proteins accumulate within nuclei of non-infected bystander cells, suggesting that STAT5/CISH signaling is effective in the entire macrophage population in our in vitro cell-based assay model.Figure 5Expression of CISH in *Mtb*-Infected Macrophages Depends on GM-CSF-Mediated STAT5 Activation(A) Analysis of STAT5 activation by immunoblotting of *Mtb*-infected human macrophages using anti-PY^694^-STAT5. Probing with anti-STAT5 and anti-α/β-tubulin antibodies was used to confirm gel loading. Immunoblots are representative of three independent experiments with three donors.(B) Typical images and quantifications of the nuclear translocation of PY-STAT5 analyzed by indirect immunofluorescence. The white arrows labeled the nuclei positive for PY-STAT5 staining. Scale bar, 20 μm. DAPI-labeled nuclei are in blue, H37Rv-GFP is in green, and PY-STAT5 is in red. Reported values represent the mean ± SD of the percentage of cells displaying STAT5 nuclear translocation. Data are representative of two independent experiments with two donors.(C) CISH mRNA expression in *Mtb* H37Rv-GFP-infected siSTAT5 and scramble human macrophages (H37Rv) for 4 hr. Non-infected (NI) cells were used as control. The data shown are the means ± SD of relative CISH mRNA expression from three independent experiments.(D) Quantification of GM-CSF release from supernatants collected from *Mtb* H37Rv-GFP-infected human macrophages for 5 or 24 hr. Reported values represent the average concentrations of cytokine released ± SEM from two donors, each tested in duplicate.(E) STAT5 activation was analyzed by immunoblotting using anti-PY^694^-STAT5 antibody. As positive control, human macrophages were treated with 50 ng/mL of human GM-CSF for 3 hr. Probing with anti-STAT5 and anti-α/β-tubulin antibodies was used to confirm gel loading.(F) Effect of neutralizing anti-GM-CSF (α-GM-CSF) on STAT5 activation in *Mtb*-infected human macrophage by western blot analysis. IgG was used as control (10 μg/mL). Reported values represent the relative STAT5 phosphorylation ± SEM. Immunoblots are representative of three independent experiments performed with human macrophages from three donors.(G) Effect of neutralizing anti-GM-CSF on CISH mRNA expression. The data correspond to the means ± SD of relative CISH mRNA expression from three independent experiments.^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001. NS, not significant.

We next investigated the impact of STAT5 downregulation on the production of CISH mRNA by qRT-PCR ([Figure S6](#mmc1){ref-type="supplementary-material"}B). Five hours after infection with *Mtb*, human macrophages silenced for STAT5 (siSTAT5) failed to induce CISH mRNA production ([Figure 5](#fig5){ref-type="fig"}C), thus indicating that STAT5 acts as a transcriptional regulator of *CISH* in macrophages.

STAT5-Mediated CISH Expression Depends on Early Release of GM-CSF by *Mtb*-Infected Macrophages {#sec2.5}
-----------------------------------------------------------------------------------------------

Finally, we wanted to identify the signal triggering the activation of STAT5 by *Mtb* in human macrophages. Because STAT proteins are known to be activated through cytokine signaling, we assessed whether such activation mechanisms occurred in our settings. STAT5 activation was thus investigated in naive human macrophages stimulated with supernatants recovered from *Mtb-*infected human macrophages. This approach revealed that STAT5 was activated in supernatant-stimulated human macrophages, which displayed phosphorylation levels similar to those observed in *Mtb*-infected macrophages ([Figure S7](#mmc1){ref-type="supplementary-material"}A). We also confirmed the nuclear translocation of STAT5 in naive human macrophages that were stimulated with supernatants recovered from *Mtb*-infected human macrophages ([Figure S7](#mmc1){ref-type="supplementary-material"}B). In contrast, no nuclear translocation of STAT5 was detectable in naive human macrophages incubated with supernatants from non-infected cells. Overall, approximately 40% of human macrophages displayed nuclear translocation of STAT5 proteins after 1.5 hr of stimulation with supernatants from infected cells. This result suggests the occurrence of a rapid *Mtb*-dependent activation of STAT5 signaling that is mediated through stimulation of molecules released by infected macrophages. In this respect, GM-CSF was previously shown to act as a possible inducer of STAT5 signaling in macrophages ([@bib16]). Accordingly, we first checked whether GM-CSF was secreted by human macrophages infected with *Mtb* in our settings and GM-CSF accumulates during the first 24 hr upon infection ([Figure 5](#fig5){ref-type="fig"}D). Next, we showed that addition of purified GM-CSF led to STAT5 phosphorylation in naive non-infected human macrophages ([Figure 5](#fig5){ref-type="fig"}E). The observed effect was blocked by the use of anti-GM-CSF (α-GM-CSF) antibodies. Such antibodies strongly impaired STAT5 activation upon infection, while PY-STAT5 levels remained unaffected in infected cells treated with control immunoglobulin G (IgG) ([Figure 5](#fig5){ref-type="fig"}F). These results strongly suggest that early secretion of GM-CSF, induced by the uptake of *Mtb* into macrophages, leads to a specific activation of STAT5 signaling. In addition, we found that treatment of cells with GM-CSF triggered CISH mRNA expression ([Figure S7](#mmc1){ref-type="supplementary-material"}C), whereas neutralization of GM-CSF during *Mtb* infection resulted in the inhibition of CISH mRNA production ([Figure 5](#fig5){ref-type="fig"}G). Altogether, these results thus allow us to propose a new complementary model of regulation for the prevention of phagosomal acidification by *Mtb* in macrophages ([Figure 6](#fig6){ref-type="fig"}). According to this new model, *Mtb* infection induces GM-CSF secretion, triggering a regulatory cascade with the nuclear translocation of STAT5 leading to the expression of CISH, which in turn ubiquitinates ATP6V1A in the immediate surrounding of *Mtb*-containing phagosomes, thus allowing the control of phagosomal acidification.Figure 6Working Model for Explaining CISH-Mediated Limitation of Acidification of Mycobacterial Phagosomes through Targeting ATP6V1A for Ubiquitination and Proteasomal DegradationProposed mechanism by which *Mtb* co-opts STAT5-mediated expression of CISH to promote V-ATPase degradation in macrophages. Right after *Mtb* uptake, early release of GM-CSF induces autocrine activation of STAT5 via the GM-CSF receptor (GM-CSF Rc). Next, activated STAT5 translocates into nucleus to induce CISH expression. CISH is then recruited and retained at the mycobacterial phagosome, where it represses phagosomal acidification by targeting ATP6V1A for ubiquitination. V-ATPases are composed of an ATP-hydrolytic domain (V~1~) and a proton-translocation domain (V~0~), acting together as a rotary machine. CISH binds and mediates ubiquitination of ATP6V1A, enabling its proteasomal degradation. The cytosolic V-ATPase was already shown to be the target of the mycobacterial tyrosine phosphatase PtpA ([@bib37]) via subunit H, suggesting that CISH and PtpA may act in synergy for an efficient blockade of phagosomal acidification.

Discussion {#sec3}
==========

Since Metchnikoff, the elucidation of the mechanisms allowing pathogens to escape the acidic defense of macrophages represents an ongoing endeavor. During phagosome maturation, lysosomal V-ATPase, considered the key enzyme involved in the process, is rapidly recruited to the phagosomal membrane for luminal acidification ([@bib32]). Because the acidification process represents a potent antimicrobial host defense, pathogenic invaders deploy an array of strategies to interfere with V-ATPase activity. For example, *Legionella pneumophila* controls phagosomal acidification through interactions of SidK with ATP6V1A ([@bib43]).

Here, we have identified a hitherto-unknown strategy developed by *Mtb* to target the V-ATPase complex, interfering with the signaling cascade of the SOCS family member CISH. As a result of this successful strategy, the phagosomal pH of *Mtb*-infected macrophages remains above the levels usually required for optimal activity of lysosomal digestive enzymes and production of reactive oxygen species ([@bib32], [@bib35]). However, previous work showed that such a lack of phagosomal acidification is also attributable to a defective fusion of the V-ATPase complex with the phagosomal membrane ([@bib31]). This effect was later ascribed to the action of PtpA, reported to be secreted by *Mtb* through the phagosomal membrane and into the cytoplasm of the host macrophage ([@bib37]). In this mechanism, PtpA binds to the subunit H of the cytosolic V-ATPase, thereby blocking its association with the phagosomal membrane and impeding phagosomal acidification. Several other mycobacterial factors have been also shown to affect early phagosome acidification in macrophages ([@bib5]). However, the molecular mechanisms underlying their action on host phagosomal proteins have not yet been precisely characterized, and it cannot be excluded that they may be involved in V-ATPase sorting.

It was considered until recently that in in vitro culture conditions, the *Mtb* phagosome remains immature for several days. Recent results obtained with sensitive flow cytometry-based cytosolic pattern recognition assays clearly suggest that *Mtb*-containing phagosomes develop membrane disruptions a few hours p.i. ([@bib2], [@bib29]). Such ESX-1 type VII secretion-dependent phagosomal rupture is consistent with the associated rapid triggering of type I interferon responses ([@bib30]) and requires inhibition of early phagosomal acidification ([@bib17], [@bib29]).

In light of our results, it is possible that the blockade of phagosomal acidification, by shutting down the V-ATPase proton pump, may be potentiated by a synergic action between CISH and PtpA. PtpA has been described to bind cellular ubiquitin or the RING domain of the TRIM27 ubiquitin ligase ([@bib36]). Thus, our findings open new questions and perspectives for research aiming to understand the possible mutual interactions between the two as-yet unconnected cellular events.

Our mechanistic model is schematically summarized in [Figure 6](#fig6){ref-type="fig"}, highlighting the host signaling pathway co-opted by the pathogen to shut down and counteract the acidification of the phagosome. The finding that the CISH protein is targeted by *Mtb* reveals a hitherto-unsuspected role for CISH, thereby providing handles for exploring mechanistic details of this previously uncharacterized antimicrobial activity of macrophages.

Our study mainly focused on the role of CISH in infected cells. In the absence of intracellular bacteria, CISH might inhibit cytokine responses in macrophages by shutting down the STAT5 signaling pathway, as is the case in T lymphocytes ([@bib38]). However, in infected macrophages, as shown here, CISH sequestration around bacteria-containing phagosomes appears to promote its activity at the phagosomal membrane. Thus, depending on the presence of intracellular bacteria, CISH-mediated processes might contribute to heterogeneous responses within the host cell population, a phenomenon that could be further investigated with single-cell approaches.

In a broader context, we could speculate that CISH-mediated control of acidification may be also used by other pathogens that have already been shown to exert effects on V-ATPase ([@bib43]). In this respect, increased susceptibility in individuals to various infectious diseases was linked to genetic polymorphisms in CISH ([@bib13]). Finally, the coexistence of different (direct and indirect) mechanisms to counteract the antimicrobial action of macrophages is observed for other infectious agents, such as in infections by *Leishmania* spp. ([@bib3]). It is intriguing that *Leishmania donovani* appears to have evolved an escape mechanism that interferes with the JAK-STAT signaling cascade of the host, although in this case, the interference concerns oxidative rather than acidic bursts and the pathway is used to inhibit the expression of inducible nitric oxide synthase (iNOS). Thus, the JAK-STAT signaling cascade represents a multifaceted host pathway that can be hijacked by different pathogens from different angles in the complex host-pathogen interaction relationships.

Experimental Procedures {#sec4}
=======================

In Vitro Intracellular Assays {#sec4.1}
-----------------------------

A recombinant strain of *Mtb* GFP-expressing *Mtb* H37Rv (H37Rv-GFP) was cultured as described in detail in the [Supplemental Information](#app2){ref-type="sec"}. RAW 264.7 cells or primary human macrophages were reverse transfected with 50 nM of siRNA for 3 days before being infected with H37Rv-GFP as detailed in the [Supplemental Information](#app2){ref-type="sec"}. Infection was allowed to proceed for 5 hr at 37°C and 5% CO~2~, and extracellular bacilli were removed via extensive washing of the plate. Antibiotics were never used at any of the multiple steps of the experiments. Infected RAW 264.7 cells were incubated at 37°C and 5% CO~2~ for 5 days. On day 5 after infection, cells were stained with 10 μM SYTO60 (Invitrogen) and confocal images were acquired using the automated fluorescence microscope Opera (PerkinElmer) as described previously ([@bib7]). Image analysis is described in detail in the [Supplemental Information](#app2){ref-type="sec"}. For the quantification of phagolysosomal fusion, living cells were labeled with 1 μM LysoTracker red DND-99 (Invitrogen) and 10 μg/mL Hoechst 33342 (Sigma-Aldrich) for 1 hr at 37°C and 5% CO~2~. For the quantification of phagosomal acidification by pHrodo, H37Rv-GFP was labeled with 0.5 mM amine-reactive pHrodo Red succinimidyl ester (Life Technologies) during 1 hr at 37°C in 100 mM sodium bicarbonate (pH 8.5) before cell infection. More details on these experiments are in the [Supplemental Information](#app2){ref-type="sec"}.

Electrophoresis and Immunoblotting {#sec4.2}
----------------------------------

After washing, cells were lysed and proteins were resolved by SDS-PAGE gels (Bio-Rad) and transferred onto a polyvinylidene difluoride (PVDF) membrane, which was probed with the appropriate antibodies as described in detail in the [Supplemental Information](#app2){ref-type="sec"}.

Immunofluorescence for Image Based-Quantification of CISH, Poly-ubiquitin, ATP6V1A, and PY-STAT5 {#sec4.3}
------------------------------------------------------------------------------------------------

After infection, human macrophages were fixed with 10% neutral buffered formalin solution (HT5014, Sigma-Aldrich) for 30 min, permeabilized, and probed with the appropriate antibodies as described in detail in the [Supplemental Information](#app2){ref-type="sec"}. For the quantification of CISH/V-ATPase colocalization around *Mtb* vacuole, confocal images were acquired using the confocal microscope Zeiss LSM880 and images were analyzed using ImageJ and the plugin JACoP ([@bib4]).

Quantification of Proteasome Activity {#sec4.4}
-------------------------------------

Proteasome activity was quantified using the Amplite Fluorimetric Proteasome 20S Activity Assay Kit from AAT Bioquest. Cells were incubated 3 hr with proteasome LLVY-R110 substrate as described in detail in the [Supplemental Information](#app2){ref-type="sec"} (where appropriate, cells were treated for 4 hr with 1 μM MG132 proteasome inhibitor).

Pull-Down of Ubiquitinated Proteins and Detection of V-ATPase Catalytic Subunit A {#sec4.5}
---------------------------------------------------------------------------------

Human macrophages were first transfected with siCISH or scramble before infection with H37Rv-GFP at a MOI of 1. Cells were lysed 24 hr p.i. Ubiquitinated proteins were then pulled down using the UbiQapture kit from Enzo Life Sciences, and proteomic analysis was performed as described in detail in the [Supplemental Information](#app2){ref-type="sec"}. For detection of endogenous V-ATPase catalytic subunit A (ATP6V1A), lysates of H37Rv-GFP-infected human macrophages were incubated for 5 hr at 4°C with 30 μL of Protein A Sepharose CL-4B beads (GE Healthcare) in the presence of rabbit anti-ATP6V1A antibody (Proteintech Europe). After electrophoresis by SDS-PAGE and transfer into the PVDF membrane, ATP6V1A was immunoblotted using rabbit anti-ATP6V1A (Novus) and secondary antibody easy blot anti-rabbit IgG conjugated with horseradish peroxidase (HRP) (GeneTex). Ubiquitin was revealed using ubiquitin-conjugated-specific HRP-linked antibody (Enzo Life Sciences).

Overexpression of Cish in HEK293 Cells {#sec4.6}
--------------------------------------

HEK293 cells (from ATCC) were transfected with pcDNA 3.1 mammalian expression vector (pcDNA)-Cish or pcDNA 3.1 (as control) using the FuGENE HD reagent (Promega) as detailed in the [Supplemental Information](#app2){ref-type="sec"}.

Human 30-Plex Cytokine Assay {#sec4.7}
----------------------------

Primary human macrophages were infected with *Mtb* H37Rv at a MOI of 1 for 5 or 24 hr; cell culture supernatants were then filtered using a 0.22 μm PVDF filter, sampled, and stored at −80°C until analysis. GM-CSF release was quantified using the Cytokine Human Magnetic 30-Plex kit (Life Technologies) according to the manufacturer's protocol.

Statistical Analysis {#sec4.8}
--------------------

In this work, statistical analyses were performed using Student's t test, with the exceptions of [Figures 3](#fig3){ref-type="fig"}B and 3F, for which the Wilcoxon Mann-Whitney test was used.

In Vivo Experiments {#sec4.9}
-------------------

Animal studies were carried out in strict accordance with the recommendations from the Animal Protection Law in Korea. The protocol was approved by the Institutional Animal Care and Use Committee of Institut Pasteur Korea. All efforts were made to minimize suffering of the animals. 6-week-old female C57BL/6 Cish KO (previously described by [@bib19]) and WT mice (ORIENTBIO, South Korea) were challenged with *Mtb* H37Rv. More details on these experiments are described in the [Supplemental Information](#app2){ref-type="sec"}.

Human Sample Analysis {#sec4.10}
---------------------

Monocytes were purified from blood samples obtained from healthy blood adult donors (age between 18 and 60 years) under strict anonymity (Etablissement Français du Sang "Nord de France," EFS, Lille). Blood samples were provided without a gender specification. The use of human samples was approved by the French Ministry of Education and Research under the agreement DC 2015-2575.
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